{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:29:46Z","timestamp":1764174586241},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T00:00:00Z","timestamp":1540512000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1038\/s41390-018-0221-7","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T08:32:17Z","timestamp":1540542737000},"page":"869-874","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Soluble receptor for advanced glycation end products as a vasculopathy biomarker in sickle cell disease"],"prefix":"10.1038","volume":"84","author":[{"given":"Nesma Ahmed","family":"Safwat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud Adel","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,26]]},"reference":[{"key":"221_CR1","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","volume":"376","author":"DC Rees","year":"2010","unstructured":"Rees, D. C., Williams, T. N. & Gladwin, M. T. Sickle- cell diseas. Lancet 376, 2018\u20132031 (2010).","journal-title":"Lancet"},{"key":"221_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3324\/haematol.2009.008938","volume":"94","author":"EJ Beers van","year":"2009","unstructured":"van Beers, E. J. et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 94, 1513\u20131519 (2009).","journal-title":"Haematologica"},{"key":"221_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cardfail.2006.11.009","volume":"13","author":"Y Koyama","year":"2007","unstructured":"Koyama, Y. et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J. Card. Faliure 13, 199\u2013206 (2007).","journal-title":"J. Card. Faliure"},{"key":"221_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2337\/dc07-1755","volume":"32","author":"EG Gerrits","year":"2008","unstructured":"Gerrits, E. G. et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 32, 517\u2013521 (2008).","journal-title":"Diabetes Care"},{"key":"221_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.diabres.2004.09.004","volume":"67","author":"N Ahmed","year":"2005","unstructured":"Ahmed, N. Advanced glycation endproducts\u2014role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 67, 3\u201321 (2005).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"221_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1365-2141.2010.08320.x","volume":"151","author":"E Nur","year":"2010","unstructured":"Nur, E. et al. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients. Br. J. Haematol. 151, 62\u201369 (2010).","journal-title":"Br. J. Haematol."},{"key":"221_CR7","unstructured":"Kay A. M., Simpson L., Stewart J. A. The role of AGE\/RAGE signaling in Diabetes-Mediated Vascular calcification. J. Diabetes Res. 2016, 6809703 (2016)."},{"key":"221_CR8","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/rheumatology\/kep199","volume":"48","author":"H Maillard-Lefebvre","year":"2009","unstructured":"Maillard-Lefebvre, H. et al. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory disease. Rheumatology 48, 1190\u20131196 (2009).","journal-title":"Rheumatology"},{"key":"221_CR9","first-page":"18","volume":"1746","author":"Q Ding","year":"2005","unstructured":"Ding, Q. & Keller, J. N. Evaluation of rage isoforms,ligands,and signaling in the brain.Biochimica et Biophysica Acta(BBA)-Molecular. Cell Res. 1746, 18\u201327 (2005).","journal-title":"Cell Res."},{"key":"221_CR10","first-page":"30032","volume":"17","author":"S Ahmad","year":"2017","unstructured":"Ahmad, S. et al. AGEs, RAGEs and sRAGE, friend or foe for cancer. Semin. Cancer Biol. 17, 30032\u201330039 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"221_CR11","first-page":"1013","volume":"62","author":"DL Wethers","year":"2000","unstructured":"Wethers, D. L. Sickle cell disease in childhood: Part I. Laboratory diagnosis, pathophysiology and health maintenance. Am. Fam. Phys. 62, 1013\u20131020 (2000).","journal-title":"Am. Fam. Phys."},{"key":"221_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJM199107043250103","volume":"325","author":"OS Platt","year":"1991","unstructured":"Platt, O. S. et al. Pain in sickle cell disease. Rates risk Factors, N. Engl. J. Med. 325, 11\u201316 (1991).","journal-title":"Rates risk Factors, N. Engl. J. Med."},{"key":"221_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jpeds.2011.07.018","volume":"160","author":"DS Darbari","year":"2012","unstructured":"Darbari, D. S. et al. Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. J. Pediatr. 160, 286\u2013290 (2012).","journal-title":"J. Pediatr."},{"key":"221_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ajh.21750","volume":"85","author":"SK Ballas","year":"2010","unstructured":"Ballas, S. K. et al. Definitions of the phenotypic manifestations of sickle cell disease. Am. J. Hematol. 85, 6 (2010).","journal-title":"Am. J. Hematol."},{"key":"221_CR15","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3324\/haematol.2011.047852","volume":"96","author":"KM Musallam","year":"2011","unstructured":"Musallam, K. M. et al. Elevated liver iron concentration is a marker of increased morbidity in patients with b thalassemia intermedia. Haematologica 96, 1605\u20131612 (2011).","journal-title":"Haematologica"},{"key":"221_CR16","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1182\/blood-2014-04-560813","volume":"124","author":"H Xu","year":"2014","unstructured":"Xu, H. et al. Sickle cell disease increases hig mobility group box 1: a novel mechanism of inflammation. Blood 124, 3978\u20133981 (2014).","journal-title":"Blood"},{"key":"221_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5581\/1516-8484.20130008","volume":"35","author":"RF Queiroz","year":"2013","unstructured":"Queiroz, R. F. & Lima, E. S. Oxidative stress in sickle cell disease. RevBras Hematol. Hemoter. 35, 16\u201317 (2013).","journal-title":"RevBras Hematol. Hemoter."},{"key":"221_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jss.2010.04.027","volume":"171","author":"F Zhang","year":"2011","unstructured":"Zhang, F. et al. The novel function of advanced glycation end products in regulation of MMP-9 production. J. Surg. Res. 171, 871\u2013876 (2011).","journal-title":"J. Surg. Res."},{"key":"221_CR19","first-page":"57","volume":"15","author":"K Parasad","year":"2006","unstructured":"Parasad, K. Soluble receptor for advanced glycation end products (sRAGE)and cardiovascular disease. Int. J. Angiol. 15, 57\u201368 (2006).","journal-title":"Int. J. Angiol."},{"key":"221_CR20","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1172\/JCI119076","volume":"98","author":"S Rajagopalan","year":"1996","unstructured":"Rajagopalan, S., Meng, X. P., Ramasamy, S., Harrison, D. G. & Galis, Z. S. Reactive oxygen Species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerosis plaque stability. J. Clin. Invest. 98, 2572\u20132579 (1996).","journal-title":"J. Clin. Invest."},{"key":"221_CR21","doi-asserted-by":"publisher","first-page":"C53","DOI":"10.1152\/ajpcell.2001.280.1.C53","volume":"280","author":"DA Siwik","year":"2001","unstructured":"Siwik, D. A., Pagano, P. J. & Colucci, W. S. Oxidative stess regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am. J. Physiol. Cell. Physiol. 280, C53\u2013C60 (2001).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"221_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2015.06.011","volume":"72","author":"AM Schmidt","year":"2015","unstructured":"Schmidt, A. M. Soluble RAGEs-Prospects for treating and tracking metabolic and inflammatory disease. Vasc. Pharmacol. 72, 1\u20138 (2015).","journal-title":"Vasc. Pharmacol."},{"key":"221_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1055\/s-0033-1363423","volume":"23","author":"K Prasad","year":"2014","unstructured":"Prasad, K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease for disease state: Myth or reality. Int. J. Angiol. 23, 11\u201316 (2014).","journal-title":"Int. J. Angiol."},{"key":"221_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408360701713104","volume":"45","author":"D Galaris","year":"2008","unstructured":"Galaris, D. & Pantopoulos, K. Oxidative stress and iron homeostasis: mechanistic and health aspects. Crit. Rev. Clin. Lab. Sci. 45, 1\u201323 (2008).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"221_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1365-2141.2004.05274.x","volume":"128","author":"SS Somjee","year":"2004","unstructured":"Somjee, S. S. et al. Advanced glycation end products in sickle cell anemia. Br. J. Hematol. 128, 112\u2013118 (2004).","journal-title":"Br. J. Hematol."},{"key":"221_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10456-008-9093-5","volume":"11","author":"JR Beijnum Van","year":"2008","unstructured":"Van Beijnum, J. R., Buurman, W. A. & Griffioen, A. W. Convergence and amplification of the toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1(HMGB1). Angiogenesis 11, 91\u201399 (2008).","journal-title":"Angiogenesis"},{"key":"221_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1474-4422(06)70469-0","volume":"5","author":"JA Switzer","year":"2006","unstructured":"Switzer, J. A., Hess, D. C., Nichols, F. T. & Adams, R. J. Pathophysiology and treatment of stroke in sickle-cell disease: present and future. Lancet Neurol. 5, 501\u2013512 (2006).","journal-title":"Lancet Neurol."},{"key":"221_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1196\/annals.1433.056","volume":"1126","author":"R Ramasamy","year":"2008","unstructured":"Ramasamy, R., Yan, S. F., Herold, K., Clynes, R. & Schmidt, A. M. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann. N. Y. Acad. Sci. 1126, 7 (2008).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"221_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/ped.2017.0814","volume":"30","author":"S Jain","year":"2017","unstructured":"Jain, S., Bakshi, N. & Krishnamurti, L. Acute chest syndrome in chidren with sickle cell disease. Pediatr. Allergy Immunol. Pulmonol. 30, 191\u2013201 (2017).","journal-title":"Pediatr. Allergy Immunol. Pulmonol."},{"key":"221_CR30","first-page":"15","volume":"403460","author":"YK Chuah","year":"2013","unstructured":"Chuah, Y. K., Basir, R., Talib, H., Tie, T. H. & Nordin, N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int. Inflamm. 403460, 15 (2013). ID.","journal-title":"Int. Inflamm."},{"key":"221_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11739-009-0300-1","volume":"4","author":"N Vazzana","year":"2009","unstructured":"Vazzana, N., Santilli, F., Cuccurullo, C. & Davi, G. Soluble forms of RAGE in internal medicine. Intern. Emerg. Med. 4, 389\u2013401 (2009).","journal-title":"Intern. Emerg. Med."},{"key":"221_CR32","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1136\/thx.2008.095588","volume":"63","author":"CS Calfee","year":"2008","unstructured":"Calfee, C. S. et al. Plasma receptor for advanced glycation end products and clinical outcomes in aute lung injuy. Thorax 63, 1083\u20131089 (2008).","journal-title":"Thorax"},{"key":"221_CR33","first-page":"9","volume":"272940","author":"R Raghupathy","year":"2010","unstructured":"Raghupathy, R., Manwani, D. & Little, J. A. Iron overload in sickle cell disease. Adv. Hematol. 272940, 9 (2010).","journal-title":"Adv. Hematol."},{"key":"221_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/03630260008993134","volume":"24","author":"SK Ballas","year":"2000","unstructured":"Ballas, S. K. & Marcolina, M. J. Determinants of red cell survival and erythropoietic activity in patients with sickle cell anemia in the steady state. Hemoglobin 24, 277\u2013286 (2000).","journal-title":"Hemoglobin"},{"key":"221_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1161\/01.ATV.0000251533.18013.67","volume":"27","author":"J Miura","year":"2007","unstructured":"Miura, J. et al. Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler. Thromb. Vasc. Biol. 27, 253\u2013254 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"221_CR36","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1007\/s00125-006-0394-1","volume":"49","author":"KC Tan","year":"2006","unstructured":"Tan, K. C. et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49, 2756\u20132762 (2006).","journal-title":"Diabetologia"},{"key":"221_CR37","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1097\/01.hjh.0000177535.45785.64","volume":"23","author":"D Geroldi","year":"2005","unstructured":"Geroldi, D. et al. Decreased plasma levels of soluble receptor for advanced glycation end products in patients with essential hypertension. J. Hypertens. 23, 1725\u20131729 (2005).","journal-title":"J. Hypertens."},{"key":"221_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00592-012-0412-3","volume":"50","author":"F Piarulli","year":"2013","unstructured":"Piarulli, F., Sartore, G. & Lapolla, A. Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol. 50, 101\u2013110 (2013).","journal-title":"Acta Diabetol."},{"key":"221_CR39","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1164\/rccm.200509-1477OC","volume":"173","author":"T Uchida","year":"2006","unstructured":"Uchida, T. et al. Receptor for advanced glycation end-products is a marker of type 1 cell injury in acute lung injury. Am. J. Resp. Crit. Care Med. 173, 1008\u20131015 (2006).","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"221_CR40","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1042\/bj20021371","volume":"370","author":"H Yonekura","year":"2003","unstructured":"Yonekura, H. et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370, 1097\u20131099 (2003).","journal-title":"Biochem. J."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41390-018-0221-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-018-0221-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-018-0221-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:24:36Z","timestamp":1684617876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-018-0221-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,26]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["221"],"URL":"https:\/\/doi.org\/10.1038\/s41390-018-0221-7","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,26]]},"assertion":[{"value":"16 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}